INHIBITION OF DAPSONE-INDUCED METHEMOGLOBINEMIA BY CIMETIDINE IN THE RAT DURING CHRONIC DAPSONE ADMINISTRATION

被引:8
作者
COLEMAN, MD
TINGLE, MD
PARK, BK
机构
[1] Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool
基金
英国惠康基金;
关键词
D O I
10.1111/j.2042-7158.1991.tb06663.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Dapsone undergoes N-acetylation to monoacetyl dapsone as well as N-hydroxylation to a hydroxylamine which is responsible for the haemotoxicity (i.e. methaemoglobinaemia; Met Hb) of the drug. Since dapsone is always given chronically, we have investigated the ability of cimetidine to inhibit Met Hb formation caused by repeated dapsone administration. The drug was given (i.p.) to four groups (n = 6 per group) of male Wistar rats, 300-360 g. Group I received 10 mg kg-1 at 1, 24, 48 and 72 h. Group II received 10 mg kg-1 at 1, 8, 24, 32, 48, 56, 72 and 80 h. Groups III and IV received the drug as for groups I and II, respectively, as well as cimetidine (50 mg kg-1) 1 h before each dose of dapsone. Twice daily dapsone administration (Group II) resulted in a significantly greater (P < 0.05) Met Hb AUC (757 +/- 135 vs 584 +/- 115% Met Hb h), dapsone AUC (140 +/- 17.5 vs 113 +/- 13.0-mu-g h mL-1) and monoacetyl dapsone AUC (48.2 +/- 18.3 vs 10.8 +/- 4.6-mu-g h mL-1) compared with a single daily dapsone dose (group I). The administration of cimetidine before the once daily dose of dapsone (group III) resulted in a significant (P < 0.05) fall in Met Hb (302 +/- 179 vs 584 +/- 115% Met Hb h) and an increase in both the dapsone (151 +/- 22.2 vs 113 +/- 13.0-mu-g h mL-1) and monoacetyl dapsone AUC values (33.6 +/- 5.8 vs 10.8 +/- 4.0-mu-g h mL-1) compared with a single daily dose of dapsone (group I). Administration of cimetidine before the twice daily dose of dapsone (group IV) resulted in no significant change in Met Hb or monoacetyl dapsone levels, despite a marked increase in the AUC after dapsone compared with control (303 +/- 53.2 vs 140 +/- 17.5-mu-g h mL-1 P < 0.05; group II). The administration of a single dose of monoacetyl dapsone alone resulted in rapid production of methaemoglobinaemia (17.1 +/- 7.2%) at 1 h; however, prior administration of cimetidine did not significantly affect methaemoglobin levels over 24 h (287.6 +/- 77.9 vs 316.4 +/- 120.2% Met Hb h). These studies indicate that although cimetidine may reduce Met Hb formation during chronic dapsone administration, dose reduction of dapsone is required to avoid haemotoxicity because of the increased accumulation of both parent drug and its monoacetyl metabolite.
引用
收藏
页码:186 / 190
页数:5
相关论文
共 27 条
[1]  
BRUCECHWATT LJ, 1982, ESSENTIAL MALARIOLOG, P81
[2]   METHEMOGLOBINEMIA PROVOKED BY MALARIAL CHEMOPROPHYLAXIS IN VIETNAM [J].
COHEN, RJ ;
SACHS, JR ;
WICKER, DJ ;
CONRAD, ME .
NEW ENGLAND JOURNAL OF MEDICINE, 1968, 279 (21) :1127-&
[3]   THE USE OF CIMETIDINE AS A SELECTIVE INHIBITOR OF DAPSONE N-HYDROXYLATION IN MAN [J].
COLEMAN, MD ;
SCOTT, AK ;
BRECKENRIDGE, AM ;
PARK, BK .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (05) :761-767
[4]   INHIBITION OF DAPSONE-INDUCED METHEMOGLOBINEMIA IN THE RAT [J].
COLEMAN, MD ;
WINN, MJ ;
BRECKENRIDGE, AM ;
PARK, BK .
BIOCHEMICAL PHARMACOLOGY, 1990, 39 (04) :802-805
[5]   BIOACTIVATION OF DAPSONE TO A CYTO-TOXIC METABOLITE BY HUMAN HEPATIC-MICROSOMAL ENZYMES [J].
COLEMAN, MD ;
BRECKENRIDGE, AM ;
PARK, BK .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 28 (04) :389-395
[6]   INHIBITION OF DAPSONE-INDUCED METHEMOGLOBINEMIA IN THE RAT ISOLATED PERFUSED LIVER [J].
COLEMAN, MD ;
HOAKSEY, PE ;
BRECKENRIDGE, AM ;
PARK, BK .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1990, 42 (05) :302-307
[7]   MICROSOMAL N-OXIDATION OF DAPSONE AS A CAUSE OF METHEMOGLOBIN FORMATION IN HUMAN RED-CELLS [J].
CUCINELL, SA ;
DAYTON, PG ;
ISRAILI, ZH .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1972, 21 (03) :322-+
[8]  
DEGOWIN RL, 1966, B WORLD HEALTH ORGAN, V35, P165
[9]   ABSORPTION METABOLISM AND EXCRETION OF DI(P-AMINOPHENYL) SULPHONE (DAPSONE) AND DI(P-AMINOPHENYL) SULPHOXIDE IN MAN [J].
ELLARD, GA .
BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY, 1966, 26 (01) :212-&
[10]  
GANER A, 1981, ISRAEL J MED SCI, V17, P703